Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria

• Published in: The New England journal of medicine Vol. 380; no. 3; pp. 229 - 241
• Main Authors: Llanos-Cuentas, Alejandro, Lacerda, Marcus V.G, Hien, Tran T, Vélez, Iván D, Namaik-larp, Chayadol, Chu, Cindy S, Villegas, Maria F, Val, Fernando, Monteiro, Wuelton M, Brito, Marcelo A.M, Costa, Mônica R.F, Chuquiyauri, Raul, Casapía, Martín, Nguyen, Chau H, Aruachan, Sandra, Papwijitsil, Ratchadaporn, Nosten, François H, Bancone, Germana, Angus, Brian, Duparc, Stephan, Craig, Graham, Rousell, Victoria M, Jones, Siôn W, Hardaker, Elizabeth, Clover, Donna D, Kendall, Lindsay, Mohamed, Khadeeja, Koh, Gavin C.K.W, Wilches, Viviana M, Breton, John J, Green, Justin A
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 17-01-2019
• Subjects: Chloroquine; Disease prevention; Drug dosages; Drug therapy; Enzymatic activity; Enzymes; Glucosephosphate dehydrogenase; Health care; Hemoglobin; Malaria; Parasitemia; Pharmaceuticals; Plasmodium vivax; Primaquine; Product development; Systematic review; Tafenoquine; Brazil; Colombia; Vietnam; Thailand; Peru
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1802537

Malaria remains a global health burden. Elimination of the hypnozoite is required in patients infected with
P. vivax
to prevent relapse. In this report, the safety of a single dose of tafenoquine was similar to that of a 14-day course of primaquine in patients with normal G6PD activity.